Development and validation of a predictive nomogram for leptomeningeal metastasis risk in NSCLC brain metastases: role of tumor location, driver mutations, and stereotactic radiosurgery - Summary - MDSpire
Advertisement
Development and validation of a predictive nomogram for leptomeningeal metastasis risk in NSCLC brain metastases: role of tumor location, driver mutations, and stereotactic radiosurgery
To identify predictors of leptomeningeal metastasis (LM) development in non-small cell lung cancer (NSCLC) patients with existing brain metastases (BM) and to develop a nomogram for clinical risk stratification, enhancing decision-making in treatment strategies.
Key Findings:
Leptomeningeal metastasis occurs in 4-7% of NSCLC patients with brain metastases, highlighting the clinical relevance of this complication.
Higher incidence of LM is associated with EGFR and ALK mutations, with specific percentages provided for clarity.
Surgical resection of brain metastases may increase the risk of subsequent LM development, warranting careful consideration in treatment planning.
Interpretation:
The study highlights the need for predictive tools to assess LM risk in NSCLC patients with BM, emphasizing the role of tumor characteristics and treatment history.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the reliability of the findings.
Limited generalizability due to the single-center study setting, which may not reflect broader patient populations.
Potential confounding factors not accounted for in the analysis could influence the results.
Conclusion:
The developed nomogram could assist in clinical decision-making by identifying NSCLC patients at high risk for LM, thereby guiding treatment strategies and potentially improving patient outcomes.
